The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Next Generation Antibody Therapeutics Market Research Report 2024

Global Next Generation Antibody Therapeutics Market Research Report 2024

Publishing Date : Feb, 2024

License Type :
 

Report Code : 1727369

No of Pages : 81

Ask Your Query

Synopsis

Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.

The global Next Generation Antibody Therapeutics market was valued at US$ 9601 million in 2023 and is anticipated to reach US$ 39450 million by 2030, witnessing a CAGR of 21.5% during the forecast period 2024-2030.

Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 percent.

This report aims to provide a comprehensive presentation of the global market for Next Generation Antibody Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next Generation Antibody Therapeutics.

Report Scope

The Next Generation Antibody Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Next Generation Antibody Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Next Generation Antibody Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • Roche
  • Amgen
  • Pfizer
  • Takeda
  • Daiichi Sankyo
  • Seagen
  • Astellas
  • Immunomedics
  • GSK
  • Immunocore
  • ADC Therapeutics

Segment by Type

  • Antibody Drug Conjugate (ADC)
  • Bispecific Antibody (BsAb)

Segment by Application

  • Cancer
  • Haemophilia
  • Other Non-Cancer Diseases

By Region

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
  • South America (Brazil, Argentina, Colombia, and Rest of South America)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next Generation Antibody Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antibody Drug Conjugate (ADC)
1.2.3 Bispecific Antibody (BsAb)
1.3 Market by Application
1.3.1 Global Next Generation Antibody Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Haemophilia
1.3.4 Other Non-Cancer Diseases
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next Generation Antibody Therapeutics Market Perspective (2019-2030)
2.2 Next Generation Antibody Therapeutics Growth Trends by Region
2.2.1 Global Next Generation Antibody Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Next Generation Antibody Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Next Generation Antibody Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Next Generation Antibody Therapeutics Market Dynamics
2.3.1 Next Generation Antibody Therapeutics Industry Trends
2.3.2 Next Generation Antibody Therapeutics Market Drivers
2.3.3 Next Generation Antibody Therapeutics Market Challenges
2.3.4 Next Generation Antibody Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next Generation Antibody Therapeutics Players by Revenue
3.1.1 Global Top Next Generation Antibody Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Next Generation Antibody Therapeutics Revenue
3.4 Global Next Generation Antibody Therapeutics Market Concentration Ratio
3.4.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 2023
3.5 Next Generation Antibody Therapeutics Key Players Head office and Area Served
3.6 Key Players Next Generation Antibody Therapeutics Product Solution and Service
3.7 Date of Enter into Next Generation Antibody Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Next Generation Antibody Therapeutics Breakdown Data by Type
4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2025-2030)
5 Next Generation Antibody Therapeutics Breakdown Data by Application
5.1 Global Next Generation Antibody Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Next Generation Antibody Therapeutics Market Size (2019-2030)
6.2 North America Next Generation Antibody Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Next Generation Antibody Therapeutics Market Size by Country (2019-2024)
6.4 North America Next Generation Antibody Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next Generation Antibody Therapeutics Market Size (2019-2030)
7.2 Europe Next Generation Antibody Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Next Generation Antibody Therapeutics Market Size by Country (2019-2024)
7.4 Europe Next Generation Antibody Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Next Generation Antibody Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next Generation Antibody Therapeutics Market Size (2019-2030)
9.2 Latin America Next Generation Antibody Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Next Generation Antibody Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Next Generation Antibody Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Next Generation Antibody Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Next Generation Antibody Therapeutics Introduction
11.1.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Next Generation Antibody Therapeutics Introduction
11.2.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Next Generation Antibody Therapeutics Introduction
11.3.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Takeda
11.4.1 Takeda Company Detail
11.4.2 Takeda Business Overview
11.4.3 Takeda Next Generation Antibody Therapeutics Introduction
11.4.4 Takeda Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.4.5 Takeda Recent Development
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Detail
11.5.2 Daiichi Sankyo Business Overview
11.5.3 Daiichi Sankyo Next Generation Antibody Therapeutics Introduction
11.5.4 Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.5.5 Daiichi Sankyo Recent Development
11.6 Seagen
11.6.1 Seagen Company Detail
11.6.2 Seagen Business Overview
11.6.3 Seagen Next Generation Antibody Therapeutics Introduction
11.6.4 Seagen Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.6.5 Seagen Recent Development
11.7 Astellas
11.7.1 Astellas Company Detail
11.7.2 Astellas Business Overview
11.7.3 Astellas Next Generation Antibody Therapeutics Introduction
11.7.4 Astellas Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.7.5 Astellas Recent Development
11.8 Immunomedics
11.8.1 Immunomedics Company Detail
11.8.2 Immunomedics Business Overview
11.8.3 Immunomedics Next Generation Antibody Therapeutics Introduction
11.8.4 Immunomedics Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.8.5 Immunomedics Recent Development
11.9 GSK
11.9.1 GSK Company Detail
11.9.2 GSK Business Overview
11.9.3 GSK Next Generation Antibody Therapeutics Introduction
11.9.4 GSK Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.9.5 GSK Recent Development
11.10 Immunocore
11.10.1 Immunocore Company Detail
11.10.2 Immunocore Business Overview
11.10.3 Immunocore Next Generation Antibody Therapeutics Introduction
11.10.4 Immunocore Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.10.5 Immunocore Recent Development
11.11 ADC Therapeutics
11.11.1 ADC Therapeutics Company Detail
11.11.2 ADC Therapeutics Business Overview
11.11.3 ADC Therapeutics Next Generation Antibody Therapeutics Introduction
11.11.4 ADC Therapeutics Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.11.5 ADC Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock